These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

727 related items for PubMed ID: 17237840

  • 1. Drug insight: vitamin D analogs in the treatment of secondary hyperparathyroidism in patients with chronic kidney disease.
    Brown AJ, Slatopolsky E.
    Nat Clin Pract Endocrinol Metab; 2007 Feb; 3(2):134-44. PubMed ID: 17237840
    [Abstract] [Full Text] [Related]

  • 2. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L.
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [Abstract] [Full Text] [Related]

  • 3. Vitamin D analogs for secondary hyperparathyroidism: what does the future hold?
    Brown AJ.
    J Steroid Biochem Mol Biol; 2007 Mar; 103(3-5):578-83. PubMed ID: 17368185
    [Abstract] [Full Text] [Related]

  • 4. Control of secondary hyperparathyroidism by vitamin D receptor agonists in chronic kidney disease.
    Sprague SM, Coyne D.
    Clin J Am Soc Nephrol; 2010 Mar; 5(3):512-8. PubMed ID: 20133492
    [Abstract] [Full Text] [Related]

  • 5. The role of vitamin D in vascular calcification in chronic kidney disease.
    Wolisi GO, Moe SM.
    Semin Dial; 2005 Mar; 18(4):307-14. PubMed ID: 16076354
    [Abstract] [Full Text] [Related]

  • 6. Survey of attitudes of physicians toward the current evaluation and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD).
    Souqiyyeh MZ, Shaheen FA.
    Saudi J Kidney Dis Transpl; 2010 Jan; 21(1):93-101. PubMed ID: 20061700
    [Abstract] [Full Text] [Related]

  • 7. Vitamin D treatment in chronic kidney disease.
    Andress DL.
    Semin Dial; 2005 Jan; 18(4):315-21. PubMed ID: 16076355
    [Abstract] [Full Text] [Related]

  • 8. Cardiovascular disease in chronic kidney failure: is there a role for vitamin D analogs?
    Wu-Wong JR, Nakane M, Traylor L, Ruan X, Kroeger PE, Tian J.
    Curr Opin Investig Drugs; 2005 Mar; 6(3):245-54. PubMed ID: 15816500
    [Abstract] [Full Text] [Related]

  • 9. Vitamin D analogs as therapeutic agents: a clinical study update.
    Wu-Wong JR, Tian J, Goltzman D.
    Curr Opin Investig Drugs; 2004 Mar; 5(3):320-6. PubMed ID: 15083599
    [Abstract] [Full Text] [Related]

  • 10. [Pathogenesis of secondary hyperparathyroidism and renal bone disease].
    Ito H, Kinugasa E.
    Clin Calcium; 2004 May; 14(5):720-5. PubMed ID: 15577032
    [Abstract] [Full Text] [Related]

  • 11. [Chronic kidney disease (CKD) and bone. Management of chronic kidney disease-mineral and bone disorder in peritoneal dialysis patients].
    Yaginuma T, Yamamoto H.
    Clin Calcium; 2009 Apr; 19(4):508-13. PubMed ID: 19329829
    [Abstract] [Full Text] [Related]

  • 12. How do calcimimetics fit into the management of parathyroid hormone, calcium, and phosphate disturbances in dialysis patients?
    Shahapuni I, Mansour J, Harbouche L, Maouad B, Benyahia M, Rahmouni K, Oprisiu R, Bonne JF, Monge M, El Esper N, Presne C, Moriniere P, Choukroun G, Fournier A.
    Semin Dial; 2005 Apr; 18(3):226-38. PubMed ID: 15934970
    [Abstract] [Full Text] [Related]

  • 13. Beyond minerals and parathyroid hormone: role of active vitamin D in end-stage renal disease.
    Wolf M, Thadhani R.
    Semin Dial; 2005 Apr; 18(4):302-6. PubMed ID: 16076353
    [Abstract] [Full Text] [Related]

  • 14. Vitamin D analogs: therapeutic applications and mechanisms for selectivity.
    Brown AJ, Slatopolsky E.
    Mol Aspects Med; 2008 Dec; 29(6):433-52. PubMed ID: 18554710
    [Abstract] [Full Text] [Related]

  • 15. Vitamin D analogues for the management of secondary hyperparathyroidism.
    Martin KJ, González EA.
    Am J Kidney Dis; 2001 Nov; 38(5 Suppl 5):S34-40. PubMed ID: 11689385
    [Abstract] [Full Text] [Related]

  • 16. Secondary hyperparathyroidism in chronic kidney disease: focus on clinical consequences and vitamin D therapies.
    Hudson JQ.
    Ann Pharmacother; 2006 Sep; 40(9):1584-93. PubMed ID: 16912241
    [Abstract] [Full Text] [Related]

  • 17. Management of secondary hyperparathyroidism in uremic patients: the role of the new vitamin D analogs.
    Brancaccio D, Cozzolino M, Galassi A, Chiarelli G, Butti A, Bellasi A, Rocca-Rey L, Volpi A, Anelli A, Zoni U, Fusaro M, Brambilla C, Missaglia E, Crovetto C, Russo M, Longhini C, Provenzano R, Incalcaterra F, Cerasola G, Li Vecchi M, Gallieni M.
    J Nephrol; 2007 Sep; 20(1):3-9. PubMed ID: 17347966
    [Abstract] [Full Text] [Related]

  • 18. Challenges in the therapy of secondary hyperparathyroidism.
    Wood C, González EA, Martin KJ.
    Ther Apher Dial; 2005 Feb; 9(1):4-8. PubMed ID: 15828898
    [Abstract] [Full Text] [Related]

  • 19. Calcitriol in the management of secondary hyperparathyroidism of renal failure.
    Daisley-Kydd RE, Mason NA.
    Pharmacotherapy; 1996 Feb; 16(4):619-30. PubMed ID: 8840368
    [Abstract] [Full Text] [Related]

  • 20. Emerging role for the vitamin D receptor activator (VDRA), paricalcitol, in the treatment of secondary hyperparathyroidism.
    Cozzolino M, Brancaccio D.
    Expert Opin Pharmacother; 2008 Apr; 9(6):947-54. PubMed ID: 18377338
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 37.